Biocept Inc (NASDAQ: BIOC) is running for the top in the market this morning, and for good reason. The company announced that it has been awarded a new United States Patent, further protecting its proprietary technology. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
BIOC Announces Patent Award
In the press release, Biocept said that it has been granted a new United States patent. The patent, number 10,745,749, is entitled “METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS.
In particular, the new patent adds further protection for the company’s Primer-Switch technology. The tech is used for the detection of rare cell mutations, including circulating tumor DNA analysis through real-time PCR and associated analysis methods. One of the most commonly used of these methods is known as next-generation sequencing, or simply NGS.
BIOC pointed to the protection this patent provides with regard to the detection of cancer found in tissue, blood, and cerebrospinal fluid. To date, this is the second patent issued for the Primer-Switch technology.
In a statement, Michael Nall, President and CEO at BIOC, had the following to offer:
Our Primer-Switch methodology has the potential to find rare mutations in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplification reactions are desired or required.
This technology builds upon our ability to detect rare genetic events in addition to our Switch-Blocker technology, which we routinely use in our ctDNA Target Selector™ assays. This is another tool in our toolkit for methods to inform on biomarkers found in tissue, blood and cerebrospinal fluid to aid physician decision making in the treatment of their patients with cancer.
This Is Big News
The news released by Biocept this morning proved to be overwhelmingly positive. The Primer-Switch technology used by the company is a game-changer in diagnostics, greatly enhancing samples for more accurate prediction of cancer mutations and other biomarkers.
It’s also worth mentioning that the company recently announced an entrance into the COVID-19 testing space. While a vaccine may be available by the end of the year, I foresee a long-term large demand for testing, on which, BIOC will be able to capitalize. Not to mention, this patent further protects technology that will likely be used in future COVID-19 testing.
The bottom line here is that the IP issued here is an important level of protection for a key technology that has the potential to change the shape of diagnostic testing, for COVID-19, cancer, and other ailments. As such, BIOC is a stock that’s well worth watching.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts!